Physician profile
Wesley Brundridge
NPI 1073932786
$7,384.43
in general payments reported to CMS, 2019-2025
16 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 82% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $145 · 2021: $60.55 · 2022: $2,219 · 2023: $1,690 · 2024: $1,257 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Travel and Lodging: $881 · Education: $88.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.52 |
| Travel and Lodging | $881.40 |
| Education | $88.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $3,315.84 | 2022-2025 | |
| Horizon Therapeutics Plc | $1,446.32 | 2020-2023 | Tepezza |
| Amgen INC. | $922.80 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $365.78 | 2023-2025 | Centurion, Clareon, Hydrus Microstent |
| Medical Device Business Services, INC. | $299.99 | 2019 | |
| Stryker Corporation | $250.24 | 2024-2025 | Na |
| Bausch & Lomb Americas INC. | $144.60 | 2024 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $107.14 | 2022 | |
| Nova Eye, INC. | $105.13 | 2025 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Ani Pharmaceuticals, INC. | $86.41 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $49.92 | 2023-2024 | Botox |
| Staar Surgical Company | $33.53 | 2019 | |
| Merz North America, INC. | $18.96 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Brundridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.